Send us Feedback

Elan Corporation (ELN)
Analysis
SUMMARY
BULLS
BEARS
TOPICS
Data
DATA CENTRAL
STOCK CHART
Financials
SEC FILINGS
BALANCE
INCOME
CASH FLOW

ELN » Topics » DUBLIN, IRELAND – September 3, 2009

This excerpt taken from the ELN 6-K filed Dec 15, 2009.
DUBLIN, Ireland – December 15, 2009 – Elan Corporation, plc and Transition Therapeutics, Inc. today notified clinical investigators of modifications to the Phase II study AD201 and open label extension study AD251 for ELND005, a compound being developed for the potential treatment of Alzheimer’s disease.  The AD201 study is evaluating three dose levels of ELND005 compared to placebo in 353 patients.

Patients will be withdrawn immediately from the study in the two higher dose groups (1000mg and 2000mg dosed twice daily).  The study will continue unchanged for patients who are assigned to the lower dose (250mg dosed twice daily) and placebo groups. The AD251 study will be modified to dose patients only at 250mg twice daily.

The decision by the companies to take these actions was made in concurrence with the Independent Safety Monitoring Committee (ISMC) following a review of the ongoing ELND005-AD201 study. Greater rates of serious adverse events, including nine deaths, were observed among patients receiving the two highest doses. A direct relationship between ELND005 and these deaths has not been established.
 
 
-1-
The ISMC and both companies concur that the tolerability and safety data are acceptable among patients receiving the 250mg dose and that the blinded study should continue for this dose and the placebo group.
 
“Today’s decision speaks to our strong commitment to patient safety while allowing for the continued evaluation of ELND005 at the 250mg dose, twice daily,” said Menghis Bairu, M.D., EVP, Chief Medical Officer and Head of Global Development at Elan. “We continue to expect the ongoing study to provide important data to guide the next steps in the development of ELND005 for the potential treatment Alzheimer’s disease.”

This excerpt taken from the ELN 6-K filed Dec 14, 2009.
DUBLIN, Ireland – December 14, 2009 – Elan Drug Technologies, a business unit of Elan Corporation, plc (NYSE: ELN) announces the approval by the Japanese Ministry of Health, Labour and Welfare of EMEND® (aprepitant) for the treatment of cancer chemotherapy-induced nausea and vomiting.  EMEND®, which was developed by a subsidiary of Merck & Co Inc., Whitehouse Station, N.J., USA and licensed to Ono Pharmaceuticals Co., Ltd. for the Japanese market, is the first licensed product approved in Japan that incorporates Elan Drug Technologies’ NanoCrystal® technology.

NanoCrystal® technology, enables formulation of poorly water soluble compounds for all routes of administration. For EMEND®, this technology advance eliminates a food requirement and improves bioavailability by 600%.  EMEND® was confirmed to be effective for both acute and delayed phases of nausea and vomiting in Japanese clinical trials, and becomes the first therapy approved for treatment of  delayed phase nausea and vomiting (24 hours or later after start of cancer chemotherapy) in Japan.

 “The approval of EMEND® is a significant achievement for our NanoCrystal® technology, as it marks the first Japanese approval of a product incorporating this technology in this very important market”, said Shane Cooke, Executive Vice President and Head of Elan Drug Technologies. “We hope this is the first of many products using our NanoCrystal® technology to be launched in Japan.”

NanoCrystal® technology is a proprietary technology developed by Elan Drug Technologies through Elan Pharma International Limited and other Elan affiliates.

 
1 
 

Five licensed products have now been approved using the NanoCrystal® technology by various health authorities including the US Food and Drug Administration (FDA). Products incorporating the NanoCrystal® technology are sold in markets worldwide.

About Elan Drug Technologies and NanoCrystal® Technology
Elan Drug Technologies (EDT), one of the world’s leading drug delivery businesses, is a business unit of Elan Corporation plc.  As a fully integrated drug delivery business, Elan Drug Technologies delivers clinically meaningful benefits to patients, by using its extensive experience and proprietary delivery technologies in collaboration with pharmaceutical companies. For 40 years, Elan Drug Technologies has been, and continues to be, a drug delivery provider of choice for a broad range of pharmaceutical companies, including many of the world’s leading pharmaceutical companies. Elan Drug Technologies offer clients drug delivery expertise with a suite of commercially launched, proprietary, technology-driven solutions, from NanoCrystal® technology for poorly water soluble compounds, to customised oral controlled release drug technologies. Products enabled by its technologies are used by millions of patients each day.  For more information go to www.elandrugtechnologies.com
 
 

 
NanoCrystal® is a registered trademark of Elan Pharma International Limited, Ireland, a subsidiary of Elan Corporation plc.
 
 
EMEND® is a registered trademark of Merck & Co Inc.
 
 

 

This excerpt taken from the ELN 6-K filed Dec 9, 2009.
DUBLIN, Ireland – December 9, 2009 – Elan Corporation, plc (NYSE: ELN) today announced that it will present at the Deutsche Bank Securities Biotech Boston Confab Conference, on Tuesday, December 15, 2009, at 10:30 a.m. Eastern Time and 3:30 p.m. GMT.
 
 
Interested parties may access a live audio web cast of the presentation by visiting the Investor Relations section of the Elan website at www.elan.com, then clicking on the event icon.  Following the live webcast, an archived version of the presentation will be available at the same URL.

About Elan
Elan Corporation, plc is a neuroscience-based biotechnology company committed to making a difference in the lives of patients and their families by dedicating itself to bringing innovations in science to fill significant unmet medical needs that continue to exist around the world. Elan shares trade on the New York and Irish Stock Exchanges. For additional information about the company, please visit http://www.elan.com.

Source: Elan Corporation, plc
###

This excerpt taken from the ELN 6-K filed Dec 4, 2009.
DUBLIN, IRELAND – December 4, 2009— Elan Drug Technologies, a business unit of Elan Corporation, plc (NYSE: ELN) announced that Janssen-Cilag has submitted a Marketing Authorisation Application (MAA) to the European Medicines Agency for paliperidone palmitate for the treatment of Schizophrenia. Paliperidone palmitate, an investigational, once-monthly atypical antipsychotic injection, utilises Elan Drug Technologies NanoCrystal® technology.

The NanoCrystal® technology, a technology enabling the formulation of poorly water soluble compounds for all routes of administration, facilitated the development of a stable, low viscosity, high drug loaded formulation of paliperidone palmitate. The application of the NanoCrystal® technology has allowed for a ready-to-use one month duration intramuscular injectable formulation to be developed. This product was approved by the US Food and Drug Administration (FDA) earlier this year.

About Elan Drug Technologies and NanoCrystal® technology
Elan Drug Technologies (EDT), the world’s leading drug delivery businesses, is a business unit of Elan (NYSE:ELN).  As a fully integrated drug delivery business, Elan Drug Technologies develops products that deliver clinically meaningful benefits to patients, by using its extensive experience and proprietary delivery technologies in collaboration with pharmaceutical companies. For 40 years, Elan Drug Technologies has been, and continues to be, a drug delivery provider of choice for a broad range of pharmaceutical companies, including many of the world’s leading pharmaceutical companies. Elan Drug Technologies offers clients drug delivery expertise with a suite

 
1 
 

of commercially launched, proprietary, technology-driven solutions, from NanoCrystal® technology for poorly water soluble compounds, to customised oral controlled release drug technologies. Products enabled by these technologies are used by millions of patients each day. For more information go to www.elandrugtechnologies.com

NanoCrystal® is a registered trademark of Elan Pharma International Limited, Ireland, a subsidiary of Elan Corporation plc (NYSE:ELN).
 

 
Safe Harbour/Forward-Looking Statements
 
 
The statements in this press release that are not historical facts are forward-looking statements that involve risks and uncertainties. A further list and description of the risks, uncertainties and other matters that confront us can be found in our Annual Report on Form 20-F for the fiscal year ended December 31, 2008, and in our Reports of Foreign Issuer on Form 6-K filed with the U.S. Securities and Exchange Commission. We assume no obligation to update any forward-looking statements, whether as a result of new information, future events or otherwise.
 
 

 
 
Source: Elan Corporation, plc
 

###

 
 
 
 
 
 
 
 
 
 
2
This excerpt taken from the ELN 6-K filed Sep 15, 2009.
DUBLIN, IRELAND – September 14, 2009 – Elan Corporation, plc (NYSE: ELN) today announced that it has cured an unintended breach of its Tysabri Collaboration Agreement with Biogen that had been identified by the United States District Court for the Southern District of New York.  Elan’s previously announced transaction with Johnson & Johnson has been amended to eliminate in its entirety the Strategic Financing and Collaboration Agreement that was the subject of the Court’s September 3, 2009, hearing and Biogen’s previously disclosed notice of breach.  Concurrently with this announcement, Elan has also informed Biogen that Elan has cured the unintended breach within the time period permitted under Elan’s Collaboration Agreement with Biogen.

 
Elan has agreed to modify the terms of its pending transaction with Johnson & Johnson, which was previously announced on July 2, 2009, to provide for the completion of all aspects of the transaction announced with the exception that the Strategic Financing and Collaboration Agreement related to Tysabri, and the subject matter of that agreement, have been eliminated and are not now included in the revised transaction.

Under the revised definitive agreement, Johnson & Johnson, through its affiliate, will invest $885 million in Elan in exchange for newly issued American Depositary Receipts (ADRs) of Elan, which will represent 18.4% of Elan's outstanding ordinary shares immediately following the closing.  In addition, as previously announced on July 2, 2009, Johnson & Johnson will acquire substantially all of the business, assets and rights of Elan related to its Alzheimer's Immunotherapy Program, through a newly formed company, Janssen Alzheimer Immunotherapy, and will initially commit up to $500 million to continue the development and launch activities of bapineuzumab, a potential first-in-class treatment that is being evaluated for slowing the progression of Alzheimer's disease, as well as other compounds.  In consideration for the transfer of these rights and assets, Elan will receive a 49.9% equity interest in Janssen Alzheimer Immunotherapy.  Elan will be entitled to a 49.9% share of the profits and certain royalty payments upon the commercialization of products under the collaboration with Wyeth.

The parties expect to close the transaction as promptly as possible.

 
 
 


About Elan
 
Elan Corporation, plc is a neuroscience-based biotechnology company committed to making a difference in the lives of patients and their families by bringing innovations in science to fill significant unmet medical needs.  Elan shares trade on the New York and Dublin Stock Exchanges.  For additional information about the company, please visit http://www.elan.com.

Forward Looking Statement
 
The statements in this press release that are not historical facts are forward-looking statements that involve risks and uncertainties.  There can be no assurance as to when or if the proposed transaction with Johnson & Johnson will be completed.  A further list and description of the risks, uncertainties and other matters that confront us can be found in our Annual Report on Form 20-F for the fiscal year ended December 31, 2008, and in our Reports of Foreign Issuer on Form 6-K filed with the U.S. Securities and Exchange Commission.  We assume no obligation to update any forward-looking statements, whether as a result of new information, future events or otherwise.
 
Save as disclosed in this announcement there has been no significant change affecting any matter contained in the original announcement of the transaction with Johnson & Johnson dated July 2nd, 2009 and, save for developments with respect to the Biogen Collaboration Agreement and the ruling made by the United States District Court for the Southern District of New York, as detailed in announcements issued by Elan dated August 6th 2009 and September 4th 2009,  no other significant new matter has arisen which would have been required to be mentioned in that earlier notification if it had arisen at the time of the preparation of that notification.
 

 
 
 



This excerpt taken from the ELN 6-K filed Sep 11, 2009.
DUBLIN, Ireland – September 10, 2009 – Elan Corporation, plc (NYSE: ELN) today announced that it will present at the Morgan Stanley Global Healthcare Unplugged Conference in New York, NY, on Monday, September 14, 2009, at 2:45 p.m. British Summer Time; and 9:45 a.m. Eastern Time.
 
Interested parties may access a live audio web cast of the presentation by visiting the Investor Relations section of the Elan website at www.elan.com, then clicking on the event icon.  Following the live webcast, an archived version of the presentation will be available at the same URL.

About Elan
Elan Corporation, plc is a neuroscience-based biotechnology company committed to making a difference in the lives of patients and their families by dedicating itself to bringing innovations in science to fill significant unmet medical needs that continue to exist around the world. Elan shares trade on the New York and Dublin Stock Exchanges. For additional information about the company, please visit http://www.elan.com.

Source: Elan Corporation, plc
 
###

This excerpt taken from the ELN 6-K filed Sep 4, 2009.
DUBLIN, IRELAND – September 3, 2009 – Elan Corporation, plc (NYSE: ELN) today issued the following statement regarding a ruling made by the United States District Court for the Southern District of New York that Elan has breached its Collaboration Agreement with Biogen Idec for the development and marketing of Tysabri:

We respect the Court’s decision and the expedited attention in this matter.  We are committed to working with Johnson & Johnson to close the transaction as quickly as possible, consistent with the Biogen-Elan Tysabri Collaboration Agreement.

About Elan
Elan Corporation, plc is a neuroscience-based biotechnology company committed to making a difference in the lives of patients and their families by bringing innovations in science to fill significant unmet medical needs.  Elan shares trade on the New York and Dublin Stock Exchanges.  For additional information about the company, please visit http://www.elan.com.

Forward Looking Statement
 
The statements in this press release that are not historical facts are forward-looking statements that involve risks and uncertainties. There can be no assurance that the proposed transaction with Johnson & Johnson can be restructured in a manner that will comport with the Court’s ruling and the terms of the Biogen Idec Collaboration Agreement and be acceptable to Johnson & Johnson and Elan. Even if such a restructuring can be agreed to, the restructured deal may be on terms materially less favorable to Elan than those currently proposed.  In addition, there can be no assurance as to when, or if, such a restructured transaction will complete.  A further list and description of the risks, uncertainties and other matters that confront us can be found in our Annual Report on Form 20-F for the fiscal year ended December 31, 2008, and in our Reports of Foreign Issuer on Form 6-K filed with the U.S. Securities and Exchange Commission. We assume no obligation to update any forward-looking statements, whether as a result of new information, future events or otherwise.
 
 
###
 



This excerpt taken from the ELN 6-K filed Aug 6, 2009.
DUBLIN, IRELAND – August 6, 2009 -- Elan Corporation, plc (NYSE: ELN) today announced that it has filed suit against Biogen Idec Inc. in Federal Court in New York seeking declaratory and injunctive relief that certain aspects of Elan’s recently announced transaction with affiliates of Johnson & Johnson (the “Transaction”) comply with Elan’s Collaboration Agreement with Biogen Idec for the development and marketing of Tysabri (the “Collaboration Agreement”).

In a letter to Elan dated July 28, 2009, Biogen Idec alleged that Elan was in material breach of the Collaboration Agreement.  Biogen Idec’s assertion against Elan relates to Elan’s ability to obtain financing from an affiliate of Johnson & Johnson to potentially purchase Biogen Idec’s Tysabri rights, if Biogen Idec undergoes a change of control.  Biogen Idec made this assertion even though it was not in possession of the relevant agreement related to the Transaction at the time, which Elan has offered to share with Biogen Idec.  Elan strongly believes that it is in compliance in all respects with the Collaboration Agreement.

Elan is committed to aggressively and proactively protecting its science, property and assets.

Elan noted in a statement, “There's nothing in the pending Transaction that is contrary to our collaboration agreement with Biogen Idec for Tysabri, an important therapeutic discovered and primarily developed by Elan.  Elan’s collaboration with Biogen Idec has been in place since 2000.  During that time, Elan and Biogen Idec have obtained regulatory approval for Tysabri in the United States, the European Union and other countries and have made the significant benefits of Tysabri available to a growing number of patients throughout these countries.  Nothing about that relationship has changed. This is the same agreement we have been operating under for the last nine years.  It is unfortunate that, because of Biogen Idec’s actions, Elan was left with no alternative but to seek court intervention to protect its interest.”

In seeking declaratory relief, Elan has requested that the Court conduct expedited proceedings given the sixty (60) day cure period following which Biogen may seek to terminate the Elan-

 
 
 

Biogen Collaboration Agreement.  Elan continues its previously stated commitment to closing the transaction with Johnson & Johnson as soon as possible.

Elan also requested that the Court enter judgment against Biogen Idec permanently enjoining Biogen Idec from terminating the Collaboration Agreement based on their July 28, 2009 Letter.

About Elan
Elan Corporation, plc is a neuroscience-based biotechnology company committed to making a difference in the lives of patients and their families by bringing innovations in science to fill significant unmet medical needs.  Elan shares trade on the New York, London and Dublin Stock Exchanges.  For additional information about the company, please visit http://www.elan.com.

Forward Looking Statement
This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995.  These forward-looking statements represent our expectations or beliefs concerning future events, and it is possible that the results described in this press release will not be achieved.  You can identify these statements by the fact that they use words such as “will”, “anticipate”, “estimate”, “expect”, “project”, “forecast”, “intend”, “plan”, “believe”, and other words and terms of similar meaning in connection with any discussion of future events.  These forward-looking statements are subject to risks, uncertainties and other factors, many of which are outside of our control, that could cause actual results to differ materially from the results discussed in the forward-looking statement, including, among other things, the risk that the Court determines that the transaction between Elan and affiliates of Johnson & Johnson violates the Collaboration Agreement and, if so, that Elan will be unable to remedy the violation prior to the expiration of the 60 day cure period commencing on the date that Biogen Idec provides Elan with a valid written notice thereof, resulting in Biogen Idec terminating the Collaboration Agreement for no consideration.  A further list and description of the risks, uncertainties and other matters that confront us can be found in our Annual Report on Form 20-F for the fiscal year ended December 31, 2008, and in our Reports of Foreign Issuer on Form 6-K filed with the U.S. Securities and Exchange Commission. We assume no obligation to update any forward-looking statements, whether as a result of new information, future events or otherwise.

###



This excerpt taken from the ELN 6-K filed Jul 8, 2009.
Dublin, Ireland – July 8, 2009 – Elan Corporation, plc (NYSE: ELN) today announced multiple presentations at the 2009 Alzheimer’s Association International Conference on Alzheimer’s Disease (ICAD 2009) in Vienna, Austria.

Elan and investigators will be present from the Alzheimer's Immunotherapy Program (AIP), a joint research, development and commercialization program between Wyeth and Elan that includes investigational clinical programs for bapineuzumab, the companies’ Phase 3 drug candidate. In addition, representatives from AIP and investigators will present eight posters analyzing various pharmacoeconomic and sociological aspects of Alzheimer’s disease (AD), including a podium presentation on the use of a claims database to estimate AD severity and costs by severity level. One additional poster will also be presented on the pharmacokinetics and pharmacodynamics of bapineuzumab.

Elan and Transition Therapeutics will be presenting three posters which discuss the nonclinical and clinical bioavailability of ELND005 (scyllo-inositol, formerly known as AZD-103) and an assay developed to measure its binding to beta amyloid. ELND005 is an orally-administered drug candidate in Phase 2 trials for the treatment of mild to moderate Alzheimer’s disease being jointly developed by Elan and Transition Therapeutics. Elan will also present a separate epidemiology poster on defining mild cognitive impairment.  In addition, investigators at University of Toronto will also present five posters highlighting results of preclinical studies with ELND005.

Details of the Elan’s presentations at ICAD are as follows:
*Note: Presentations are listed by date and all times are listed in Central European Time




 
1
 



AIP Pharmacoeconomic and Sociological Analyses

Poster P1-204: Estimating Health-Related Quality of Life for Unique Dependence Levels in Patients with Alzheimer ’s Disease
Sunday, July 12, 12:30- 2:30 PM

Poster P1-212: Estimated Dependence Scale Scores Based on Clinical Dementia Rating - Sum of Boxes Scores in Patients with Mild Cognitive Impairment or Mild to Moderate Alzheimer’s Disease
Sunday, July 12, 12:30- 2:30 PM

Poster P1-180: Relationship between Patient Dependence on others and Caregiver Burden in Alzheimer’s Disease (AD)
Sunday, July 12, 12:30- 2:30 PM

This excerpt taken from the ELN 6-K filed Jun 3, 2009.
DUBLIN, Ireland – June 3, 2009 – Elan Corporation, plc (NYSE: ELN) today announced that it will present at the Goldman Sachs 30th Annual Global Healthcare Conference in New York, NY, on Wednesday, June 10, 2009, at 7:30 p.m. British Summer Time; and 2:30 p.m. Eastern Time.

Interested parties may access a live audio web cast of the presentation by visiting the Investor Relations section of the Elan website at www.elan.com, then clicking on the event icon.  Following the live webcast, an archived version of the presentation will be available at the same URL.

About Elan
Elan Corporation, plc is a neuroscience-based biotechnology company committed to making a difference in the lives of patients and their families by dedicating itself to bringing innovations in science to fill significant unmet medical needs that continue to exist around the world. Elan shares trade on the New York, London and Dublin Stock Exchanges. For additional information about the company, please visit http://www.elan.com.

Source: Elan Corporation, plc
###
 
 
 

1
This excerpt taken from the ELN 6-K filed Mar 12, 2009.
DUBLIN, Ireland – March 12, 2009 – Elan Corporation, plc (NYSE: ELN) today announced that it will present at the Cowen and Company 29th Annual Health Care Conference in Boston, MA on Thursday, March 19, 2009 at 8:05 a.m. PDT, 11:05 a.m. EDT, 3:05 p.m. GMT.  The presentation will be followed by a breakout session.

Interested parties may access a live audio web cast of the presentation by visiting the Investor Relations section of the Elan website at www.elan.com, then clicking on the event icon.  Following the live webcast, an archived version of the presentation will be available at the same URL.

About Elan
Elan Corporation, plc is a neuroscience-based biotechnology company committed to making a difference in the lives of patients and their families by dedicating itself to bringing innovations in science to fill significant unmet medical needs that continue to exist around the world. Elan shares trade on the New York, London and Dublin Stock Exchanges. For additional information about the company, please visit http://www.elan.com.

Source: Elan Corporation, plc
###
 
 
 
1
This excerpt taken from the ELN 6-K filed Feb 25, 2009.
Dublin, Ireland – February 25, 2009 – Elan Corporation, plc (NYSE: ELN) announced today that, as previously guided, and as part of its ongoing efforts to consistently and rigorously manage its overall cost base and direct additional investment toward its promising and late stage pipeline, it will refine its business operations and functions to realize greater efficiencies and deepen its commitment and focus to key and strategic areas.

The holding company, Elan Corporation, plc, will continue to have two related but distinct operating divisions: Biopharmaceuticals and Elan Drug Technologies.

Specific adjustments include a postponement of biologics manufacturing activities, a strategic redesign and realignment of the R&D organization within the Biopharmaceutical business, and a reduction in related G&A and other support activities. These changes follow the realignment of components of Elan’s commercial organization announced in late 2008.

These adjustments, largely driven by changes in the Biopharmaceuticals business, will result in a reduction in Elan’s global workforce of approximately 230 positions, or 14% of Elan’s workforce.   In Ireland, where Elan’s biological manufacturing and related fill finish activities are based, approximately 115 positions will be impacted.  A further approximately 115 positions will be affected in the United States, mainly in the areas of research, clinical development, biopharmaceutical development, and related corporate support and administrative services.  Elan expects to reassess the opportunity to invest in a biologics manufacturing facility and restart its related fill finish activities after the company has had the opportunity to evaluate the data from the Phase 3 trials of bapineuzumab in Alzheimer’s disease.

Elan expects that the financial benefits of these adjustments, some of which will be re-invested in the advancement of the clinical development of its pipeline, will reduce operating expenses in 2009 by $30-$35 million and by approximately $50 million in a full year.  Severance and related charges are expected to be $15 million and will be recorded as a charge in the first half of 2009.

Following these planned changes, Elan reiterates its financial guidance for 2009 and expects revenue to grow by double digit percentages, to be Adjusted EBITDA profitable for the year, and to end the year with cash and investment balances in the region of $200 million.

 
1 
 

Elan CEO Kelly Martin said this internal realignment was driven in large part by an assessment of the Biopharmaceuticals division completed by Dr. Carlos V. Paya, who joined Elan as President late last year. The internal business review was conducted in addition to and separately from the previously announced and on-going corporate strategic review process which, should it be successful, may bring additional capabilities to Elan and further augment the company’s improved financial performance and increased revenues reported in 2008.

Mr. Martin said, “As we continue to advance the company, we remain committed to the precise and specific investment in new talent, new technologies and novel therapeutic opportunities in the neuroscience field. This will further strengthen our core business areas that bring the greatest potential value to patients and shareholders, and enable us to invest in our most valuable programs within the Biopharmaceuticals and Elan Drug Technologies businesses.”

Dr. Paya said that following the changes, Elan is well positioned in the biopharmaceutical industry. “We are creating a forward-thinking, flexible, science-based and patient-focused business supported by modest infrastructure,” Dr. Paya said. “This model maximizes our opportunities and leverages our unique innovation, talent, experience and pipeline.”

Dr. Paya said that further progress would enable Elan to leverage a highly focused and cost-advantaged organization, with a foundation to become the world’s leading neuroscience company.  Dr. Paya added, “This realignment has been strategically driven and will enable us to further focus on our four key near-and intermediate-term priorities: driving uptake of Tysabri, advancing our Alzheimer’s programs, harnessing the value of our pipeline, and maximizing the growth of EDT.”


About Elan
Elan Corporation, plc is a neuroscience-based biotechnology company committed to making a difference in the lives of patients and their families by bringing innovations in science to fill significant unmet medical needs.  Elan shares trade on the New York, London and Dublin Stock Exchanges. For additional information about the company, please visit www.elan.com.
 
Forward Looking Statement  
 
 
The statements in this press release that are not historical facts are forward-looking statements that involve risks and uncertainties. In particular, this realignment may not result in greater efficiencies or focus, the projected reductions in operating expenses may not be realized, severance and related costs of the realignment may be higher than anticipated, our financial guidance may not be achieved, our corporate strategic review may not be successful and our core business areas may not be strengthened. A further list and description of the risks, uncertainties and other matters that confront us can be found in our Annual Report on Form 20-F for the fiscal year ended December 31, 2007, and in our Reports of Foreign Issuer on Form 6-K filed with the U.S. Securities and Exchange Commission. We assume no obligation to update any forward-looking statements, whether as a result of new information, future events or otherwise.
 
###
 
 
2
This excerpt taken from the ELN 6-K filed Jan 13, 2009.
DUBLIN, Ireland – January 13, 2009 – Elan Corporation, plc (NYSE: ELN) today clarified recent reports that the duration of the bapineuzumab Phase 3 clinical trials may be extended.  The protocols for the four Phase 3 trials for bapineuzumab, which are approved by regulatory authorities, are designed for patients to participate for a duration of 18 months.  The planned duration of the trials has not changed since the program was announced in December 2007.  There are currently no plans to extend the duration of the Phase 3 trials.

The erroneous reports first appeared on Bloomberg News. Bapineuzumab is being developed jointly by Elan and Wyeth (NYSE: WYE).

About Elan
Elan Corporation, plc is a neuroscience-based biotechnology company committed to making a difference in the lives of patients and their families by dedicating itself to bringing innovations in science to fill significant unmet medical needs that continue to exist around the world. Elan shares trade on the New York, London and Dublin Stock Exchanges. For additional information about the company, please visit http://www.elan.com.

Forward Looking Statement

The statements in this press release that are not historical facts are forward-looking statements that involve risks and uncertainties. A further list and description of the risks, uncertainties and other matters that confront us can be found in our Annual Report on Form 20-F for the fiscal year ended December 31, 2007, and in our Reports of Foreign Issuer on Form 6-K filed with the U.S. Securities and Exchange Commission. We assume no obligation to update any forward-looking statements, whether as a result of new information, future events or otherwise.

Source: Elan Corporation, plc
###
 
 
 

EXCERPTS ON THIS PAGE:

6-K
Dec 15, 2009
6-K
Dec 14, 2009
6-K
Dec 9, 2009
6-K
Dec 4, 2009
6-K
Sep 15, 2009
6-K
Sep 11, 2009
6-K
Sep 4, 2009
6-K
Aug 6, 2009
6-K
Jul 8, 2009
6-K
Jun 3, 2009
6-K
Mar 12, 2009
6-K
Feb 25, 2009
6-K
Jan 13, 2009

RELATED TOPICS for ELN:

Wikinvest © 2006, 2007, 2008, 2009, 2010, 2011, 2012. Use of this site is subject to express Terms of Service, Privacy Policy, and Disclaimer. By continuing past this page, you agree to abide by these terms. Any information provided by Wikinvest, including but not limited to company data, competitors, business analysis, market share, sales revenues and other operating metrics, earnings call analysis, conference call transcripts, industry information, or price targets should not be construed as research, trading tips or recommendations, or investment advice and is provided with no warrants as to its accuracy. Stock market data, including US and International equity symbols, stock quotes, share prices, earnings ratios, and other fundamental data is provided by data partners. Stock market quotes delayed at least 15 minutes for NASDAQ, 20 mins for NYSE and AMEX. Market data by Xignite. See data providers for more details. Company names, products, services and branding cited herein may be trademarks or registered trademarks of their respective owners. The use of trademarks or service marks of another is not a representation that the other is affiliated with, sponsors, is sponsored by, endorses, or is endorsed by Wikinvest.
Powered by MediaWiki